Monoparin-Ca (Heparin Calcium)

Heparin calcium, the active ingredient in Monoparin-Ca, is an anticoagulant presented as a sterile injectable for intravenous and subcutaneous use. It is employed to prevent and treat venous thromboembolism and to provide anticoagulation during cardiac surgery and other invasive procedures.

GNH USA supplies Monoparin-Ca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Monoparin-Ca is used within the anticoagulation pathway to manage clot‑related conditions.

Venous thromboembolism: prevents formation and propagation of clots in deep veins and lungs. Deep vein thrombosis prophylaxis: reduces incidence of postoperative DVT in surgical patients. Cardiac surgery anticoagulation: maintains therapeutic anticoagulation during cardiopulmonary bypass and other invasive cardiac procedures.

Common Side Effects: - Bleeding: excessive or unexpected bleeding at sites of injection or elsewhere. - Hematoma: localized swelling due to blood accumulation under the skin. - Local pain or irritation at the injection site. - Nausea or mild gastrointestinal discomfort. - Elevated activated partial thromboplastin time (aPTT) observed in laboratory monitoring. - Mild thrombocytopenia: slight reduction in platelet count.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation leading to paradoxical clotting. - Major hemorrhage: intracranial, gastrointestinal, or retroperitoneal bleeding. - Severe allergic reactions: urticaria, angioedema, or anaphylaxis. - Osteoporosis with prolonged therapy: decreased bone mineral density. - Spontaneous adrenal hemorrhage. - Severe liver enzyme elevation indicating hepatic injury.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor laboratory parameters.

Renal impairment: adjust monitoring and consider dose modification. Pregnancy: evaluate risk‑benefit ratio and use only if clearly indicated. Surgery or invasive procedures: discontinue appropriately to reduce bleeding risk. Concomitant anticoagulants: avoid additive bleeding by reviewing all antithrombotic agents. History of HIT: avoid use and select alternative anticoagulant. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Heparin calcium may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk. - Antiplatelet agents (aspirin, clopidogrel): additive hemorrhagic effect. - Fibrinolytic therapy (tPA, streptokinase): heightened risk of severe bleeding.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): may exacerbate minor bleeding. - Cimetidine: can elevate heparin plasma levels, increasing anticoagulant effect. - ACE inhibitors: may potentiate hypotensive episodes when combined with heparin.